Alamar Biosciences (ALMR) Q2 2026 earnings review
Consumables Surge Drives Revenue Beat, But OpEx Ramp Widens Losses
Alamar Biosciences delivered strong Q2 2026 results with total revenue up 82% YoY to $29.4M, driven by an accelerating 147% surge in high-margin consumables. This favorable mix shift pushed gross margins to a robust 60%. However, the company is heavily reinvesting its recent April 2026 IPO proceeds: operating expenses spiked 89% YoY, widening the net loss to $13.2M. The company issued confident FY26 revenue guidance of $116-120M, though a sharp deceleration in new instrument placements warrants close monitoring.
🐂 Bull Case
Consumable revenue is severely outpacing instrument growth, proving that the installed base is highly engaged and aggressively utilizing the platform for multiplex panels.
Armed with $256.3M in cash and short-term investments following its April IPO, Alamar has ample runway to fund its aggressive R&D and commercial expansion plans without near-term liquidity concerns.
🐻 Bear Case
Instrument revenue growth decelerated sharply from 78% YoY in Q1 to 35% YoY in Q2, suggesting potential saturation or elongated sales cycles for core hardware.
Despite 82% revenue growth and expanding gross margins, operating losses worsened from $7.9M to $13.5M YoY. SG&A costs more than doubled YoY, reflecting heavy public company and commercial expansion burdens.
⚖️ Verdict: 🟢
Bullish. The 147% growth in high-margin consumables perfectly validates the long-term business model. The widening losses are acceptable at this early post-IPO commercial stage, given the massive $256M cash cushion.
Key Themes
Consumables Accelerating Gross Margin Expansion
The revenue mix is rapidly shifting toward high-margin consumables, which surged 147% YoY to $15.5M. This mix shift, combined with manufacturing efficiencies, drove an accelerating gross margin trend from 49% in 25Q1 to 53% in 25Q2, 56% in 26Q1, and now 60% in 26Q2. If this trajectory holds, long-term profitability metrics will improve drastically once operating leverage kicks in.
Instrument Growth Decelerating
While total revenue growth is impressive, the core hardware engine is showing signs of fatigue. Instrument revenue grew 35% YoY to $7.8M, which is a steep deceleration from the 78% YoY growth recorded just one quarter ago in 26Q1. While current consumable pull-through is strong, future consumable growth relies on continuously expanding the instrument installed base.
Rapid Pipeline Innovation: Neuro and Immune Launches
Alamar successfully launched two critical commercial assets: the NULISAseq Neuro 220 Panel (featuring the first commercial multiplexed blood-based immunoassay for eMTBR-tau for Alzheimer's) and the NULISAseq Immune 340 Panel. Expanding into neurodegenerative diseases and broad immune profiling significantly expands the total addressable market and justifies the heavy R&D spend.
Aggressive OpEx Expansion Eclipses Top-Line Gains
Operating expenses jumped 89% YoY to $31.2M. SG&A was the main culprit, surging 129% YoY to $17.4M, driven by new headcount, infrastructure, and the newly added costs of being a public company following the April IPO. This lack of operating leverage means net losses will likely remain elevated in the near term despite spectacular revenue beats.
Other KPIs
Total cash, equivalents, and short-term investments sit at a massive $256.3M, up from just $34.9M at the end of FY25. This war chest, fortified by $197.8M in net proceeds from the April 2026 IPO, heavily de-risks the balance sheet against the current quarterly operating cash burn.
Services revenue grew a stable 49% YoY. While overshadowed by the massive consumable beat, stable growth in this segment indicates healthy ongoing adoption of Alamar's Technology Access Program by researchers.
Guidance
Management issued its first full-year guidance post-IPO, targeting 59% YoY growth at the midpoint compared to FY25. Given that H1 2026 revenue was $55.4M, achieving the $118M midpoint implies H2 2026 revenue of roughly $62.6M, signaling expectations for continued, stable commercial acceleration in the back half of the year.
Key Questions
Instrument Deceleration
Instrument revenue growth decelerated from 78% YoY in Q1 to 35% in Q2. Is this due to natural lumpiness in capital equipment cycles, or are you seeing elongated sales cycles and budget constraints among academic and biotech customers?
OpEx Normalization
SG&A expenses grew 129% YoY this quarter. As the initial costs of the IPO and new public company infrastructure normalize, at what point do you expect operating expense growth to meaningfully decouple from revenue growth?
eMTBR-tau Commercialization
With the launch of the eMTBR-tau immunoassay, what are the early indicators of demand from the biopharma sector for Alzheimer's clinical trial applications, and how much is this expected to contribute to the H2 revenue guide?